Virginia is currently home to 1859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126
Recruiting
The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
Cardioprotection in AML
NCT04977180
Recruiting
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart. Beta blockers and angiotensin-converting enzyme inhibitors (ACEi) are two types of drugs that are often used (and are FDA approved) to treat the type of damage to the heart caused by anthracyclines. They have also been used in some populations to prevent this type of heart damage. In this study, particip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: AML, Acute Myeloid Leukemia
Register for Updates
Research Participation With Transgender and Gender-Diverse Youth
NCT05927350
Recruiting
Research has historically excluded the participation of transgender and gender-diverse people. The purpose of this research study is to find out about what goes into a transgender and gender-diverse youth's decision to participate in research. The results of this study will be used to improve access to research for transgender and gender-diverse youth and therefore, improve the representation of transgender and gender-diverse youth as research participants in research.
Gender:
ALL
Ages:
Between 15 years and 21 years
Trial Updated:
02/17/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Transgender Persons
Register for Updates
Food Orders on Blood Glucose and Fuel Use At Rest
NCT06763562
Recruiting
Consuming a carbohydrate-rich food as the final food in a meal, as compared to the first food in a meal, has been shown to reduce blood glucose levels after eating in both diabetes patients and in healthy controls. However, gaps remain in the literature in this area of research, and currently little is known about how substrate (fuel) use is impacted by altering food order. In addition, most studies to date have used a mix of meat and plant foods, while little research has focused exclusively on... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/16/2025
Locations: Old Dominion University Human Performance Laboratory, Norfolk, Virginia
Conditions: Glucose Metabolism Disorders, Hunger, Fat Burn
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence
NCT05616208
Recruiting
This is first-in-human prospective Phase I study of the immediate and long-term safety of an implanted internal anal sphincter (IAS) bioengineered from autologous cells to treat subjects with severe passive FI who have failed standard treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Virginia Commonwealth University Health Main Hospital (VCU), Richmond, Virginia
Conditions: Fecal Incontinence
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Charlottesville, Virginia
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
NCT06830629
Recruiting
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Virginia Nephrology Group, Arlington, Virginia
Conditions: Proteinuric Kidney Disease
Register for Updates
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
NCT06659055
Recruiting
The purpose of this research is to collect medical imaging data to allow for the comparison of bone mineral density measurements from two different types of low-dose x-ray exams, EOSedge and conventional DXA. The main question it aims to answer is: Is there agreement between the calculated T-scores between the 2 different types of x-ray exams?
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/12/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Healthy, Indicated for EOSedge Imaging
Register for Updates
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
NCT06106672
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Register for Updates
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Warrenton, Virginia
Conditions: Geographic Atrophy
Register for Updates
Left vs Left Randomized Clinical Trial
NCT05650658
Recruiting
The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Register for Updates